Are ibogaine clinical trials available in the United States in 2026?

Yes, U.S. clinical research is active or preparing through academic and state-funded programs, especially after Texas awarded $50 million to UTHealth Houston and UTMB Health. Availability is limited and depends on enrollment criteria, location, medical screening, and IND-authorized protocols.

Is ibogaine FDA-approved for opioid addiction?

No. As of May 2026, ibogaine remains Schedule I and is not FDA-approved for opioid use disorder, alcohol use disorder, PTSD, or any other indication. Legal U.S. access is generally limited to clinical trials or rare expanded-access pathways.

When could ibogaine be FDA-approved?

The realistic approval window cited in 2026 analyses is 2030–2032. Breakthrough Therapy designation could accelerate review, but full approval still requires rigorous Phase 2b/3 or Phase 3 evidence and a safety package acceptable to the FDA.

What is the biggest safety concern in ibogaine trials?

Cardiac safety, especially QTc prolongation, is the central concern. Serious protocols use baseline ECG screening, medication review, laboratory testing, and continuous ECG telemetry during the acute 24–38 hour period.

Does ibogaine cure addiction in one treatment?

No. Observational studies suggest some patients experience months of reduced craving or abstinence, but ibogaine is not a guaranteed or permanent cure. Long-term outcomes depend on follow-up care, psychotherapy, social support, and individual medical and psychiatric factors.

How does ibogaine differ from methadone or buprenorphine?

Methadone and buprenorphine are evidence-based maintenance medications taken regularly and known to reduce overdose risk. Ibogaine is being studied as an intensive episodic intervention that may suppress withdrawal and craving without daily dosing. It is a different treatment model, not a universal replacement.

Can I legally receive ibogaine treatment outside a U.S. trial?

Not in routine U.S. medical care. Some people travel to countries where ibogaine clinics operate, such as Mexico, but those treatments are not FDA-approved and may vary widely in screening, monitoring, manufacturing quality, and follow-up.

Who should not consider ibogaine clinical trial enrollment?

People with arrhythmias, prolonged QT syndrome, serious cardiac disease, uncontrolled hypertension, severe liver disease, active psychosis, unstable bipolar disorder, or interacting medications may be excluded. Only a qualified trial team can determine eligibility.

What should I ask a trial coordinator before enrolling?

Ask whether the study is IND-authorized, what cardiac monitoring is used, what medications are excluded, how long observation lasts, what endpoints are measured, and what recovery support is provided after discharge.

Contact

Ibogatrack is an independent information resource on ibogaine for people researching ibogaine. If you have corrections, questions, or feedback about the site, we welcome concise notes so our coverage stays accurate and useful.

Invitation: corrections, factual clarifications, or suggestions about editorial approach are appreciated.

Close-up natural light photograph accompanying contact information for Ibogatrack

How to reach Ibogatrack

At present there are no public email addresses or forms published on this site. The site can be reached through its published channels; please check back for contact details or updates about our editorial process. For background on our approach, see the page describing our editorial approach with a short overview on the site's goals at the about page, which explains how we source and verify content.

Corrections & feedback

If you notice an error or have a factual correction, please consult the editorial notes on our about page for guidance on what information we collect before contacting us. That page explains the site's mission and how we handle updates.

Where this page sits

If you arrived here from an article or an external mention, you can navigate back to the site's entry point using the site index; a brief guide to the site's scope and values is available via a link to the homepage's overview in the site navigation and also in context on the front page, which outlines our focus on evidence, safety, legality and practical questions about ibogaine in Texas.

Ibogatrack is an independent information resource. It is not a clinic, medical provider, or licensed treatment center, and its content is not medical or legal advice.